You can’t win them all. Following are recent picks in biotech, metals and technology that didn’t quite pan out.
On May 11st, The Negotiator was bullish on biotech. He said, “Would you like to know the way I play bio tech? Gilead (GILD) is a personal favorite. Tamiflu and 9 other drugs; 5 stocks in clinical trials."
But shares have since fallen -- the stock was hurt Wednesday by two analyst downgrades.
Today Guy says he still likes this stock and is buying it on the dip.